Researchers look for smaller, cheaper, one-dose vaccines

Michael Wannemuehler and his team of researchers is hoping to find a way to produce vaccines that work better, use smaller doses and require only one trip to the doctor's office.

Traditionally, injectable vaccines have often been prepared from killed bacteria. The vaccinated person's immune system then learns to recognize the bacteria as a threat and consequently builds up defenses against it. Then, if the individual is exposed to the live version of the infectious agent, his or her body is already prepared to defend itself.

Wannemuehler's research is focused on the use of just a part of the bacteria -- a protein -- as a vaccine, instead of the entire bacteria, coupled with novel polymers that will be used to deliver these vaccines. This combination of new approaches will allow vaccines doses to be smaller, safer and induce fewer side effects.

"As we move away from using whole bacteria, we're going to more molecular approaches with purified proteins or portions of proteins," said Wannemuehler, a professor of veterinary microbiology and preventative medicine. "What these technologies should allow us to do is, instead of injecting 100 units to get protection, we can inject one unit, for example."

Wannemuehler's research targets the bacteria that causes plague, a disease that's rare in the United States, but is still found in other parts of the world.

Using select proteins of the bacteria coupled with unique polymers can reduce the amount of vaccine needed as well as costs for shipping and storage. That makes the vaccine economically feasible for areas at a great distance, such as Africa, where vaccines can be difficult to obtain.

Also, vaccinating a large population can be difficult if more than one dose or injection is required. In places where doctors are scarce, locating and vaccinating patients can be difficult. In addition, having the same patients return for their booster vaccinations can be even more complicated.

"Another aspect is the hope that this would be single dose," said Wannemuehler. "We hope we can get a robust response with one dose."

And there will likely be uses beyond the plague.

"If this technology works here," said Wannemuehler, "it's completely transferable to any protein, with minor changes."

Wannemuehler is working with BioProtection Systems Corp. of Ames on this research. BPSC hopes to supply lower-cost vaccines to government agencies for use where the plague is still a threat.

"We are thankful that the Iowa Values Fund supports our collaboration with Iowa State University and allows us to combine our broadly applicable vaccine technology with theirs for the development of more effective vaccines," said Joe Lucas of BPSC, located at the Iowa State University Research Park.

Source: Iowa State University

Whooping cough cases on the rise in Midwest
An underreported, often misdiagnosed disease that people think affects only young children is drawing concern from national health officials and has recently struck hospital workers, closed schools in the Midwest and kept multiple health departments busy sending out alerts.
UCLA develops safer, more effective TB vaccine for HIV-positive people
UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials.
Researchers develop cross-protective vaccine
(PhysOrg.com) -- Doctors have always hoped that scientists might one day create a vaccination that would treat a broad spectrum of maladies. They could only imagine that there might be one vaccine that would protect against, say, 2,500 strains of Salmonella. And what if that same vaccine could help protect the elderly?
Researchers discover how infectious bacteria can switch species
Scientists from the Universities of Bath and Exeter have developed a rapid new way of checking for toxic genes in disease-causing bacteria which infect insects and humans. Their findings could in the future lead to new vaccines and anti-bacterial drugs.
Groundbreaking, lifesaving TB vaccine a step closer
Researchers at Aberystwyth University, following a number of years of investment by the Biotechnology and Biological Sciences Research Council (BBSRC), have licensed ground-breaking research to a non-profit product development partnership working to develop new, more effective vaccines against Tuberculosis (TB). This development will give hope that significantly better prevention and treatment of TB will be available within the next few years.
New vaccines may not reduce TB incidence
(PhysOrg.com) -- Despite the potential of new vaccines to prevent TB, new research shows that the removal of one strain of TB can allow a previously suppressed strain to succeed. Consequently, a vaccination program could result in the proliferation of strains more likely to be, or become, drug resistant, and could even result in an increased prevalence of the disease.
Why some primates, but not humans, can live with immunodeficiency viruses and not progress to AIDS
Key differences in immune system signaling and the production of specific immune regulatory molecules may explain why some primates are able to live with an immunodeficiency virus infection without progressing to AIDS-like illness, unlike other primate species, including rhesus macaques and humans, that succumb to disease.
Bacteria's sticky glue is clue to vaccine says scientist
Sticky glue secreted by the bacterium Staphylococcus aureus could be the clue scientists have been searching for to make an effective vaccine against MRSA, medical researchers heard today at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.

Researchers look for smaller, cheaper, one-dose vaccines

Related stories:

News discussion: